Ghia Canna Jagdish, Rambhad Gautam Sudhakar
Medical and Scientific Affairs, Pfizer Limited, Mumbai, Maharashtra, India.
Microbiol Insights. 2021 Nov 29;14:11786361211053344. doi: 10.1177/11786361211053344. eCollection 2021.
To perform systematic review and meta-analysis of meningococcal disease burden in India.
We searched publications on meningococcal disease in India between 1996 and 2020 using PubMed and Google Scholar. Prevalence (proportion) of and Case-fatality ratio (CFR) were pooled using random effects model. Other outcomes were pooled qualitatively.
The prevalence of in epidemic and endemic conditions was 12.1% (95% CI: 5.2-21.4) and 0.76% (95% CI: 0.3-1.4), respectively, with a CFR of 12.8% (95% CI: 6.8-20.4) in epidemic settings; caused 3.2% (95% CI: 1.6-5.3) of Acute Bacterial Meningitis (ABM) cases in endemic settings. The disease appeared in infants, adolescents, and adults with Serogroup A prevalence. Treatment and prophylaxis were limited to antibiotics despite increased resistance.
The study reveals epidemic and endemic presence of the disease in India with high fatality and serogroup A prevalence. Further monitoring and immunization are required to prevent outbreaks.
对印度脑膜炎球菌病负担进行系统评价和荟萃分析。
我们使用PubMed和谷歌学术搜索了1996年至2020年间印度关于脑膜炎球菌病的出版物。使用随机效应模型汇总患病率（比例）和病死率（CFR）。其他结果进行定性汇总。
在流行和地方性流行情况下，[病原体名称]的患病率分别为12.1%（95%置信区间：5.2 - 21.4）和0.76%（95%置信区间：0.3 - 1.4），在流行环境中病死率为12.8%（95%置信区间：6.8 - 20.4）；在地方性流行环境中，[病原体名称]导致3.2%（95%置信区间：1.6 - 5.3）的急性细菌性脑膜炎（ABM）病例。该疾病在A群血清型流行的婴儿、青少年和成人中出现。尽管耐药性增加，但治疗和预防仅限于使用抗生素。
该研究揭示了印度存在该疾病的流行和地方性流行情况，病死率高且A群血清型流行。需要进一步监测和免疫接种以预防疫情爆发。
